🎗️ Ovarian Cancer Suidan Score (Suboptimal Cytoreduction Prediction)
UseSupport the primary-debulking vs neoadjuvant-chemotherapy decision in advanced ovarian/tubal/peritoneal cance…
Loading calculator…
SourceSuidan RS, et al. A multicenter prospective trial evaluating the ability of preoperative CT scan an…
Runs locally in your browser (no PHI uploaded). For licensed clinicians — not a substitute for clinical judgement.
Stored on this device for revisit reminders
This-shift next steps
After scoring: open the scene pack, peer scores, and the matching pathway. Local reference — no HIS write.
Scene next step
📋gyn oncoOpen scene pack →Related scores
Matching pathway
🧭cervical_ca_mriOpen pathway →Score + version; reference only — not a substitute for care · no HIS write
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
Methodology · worked example, guidelines & full notes
Clinical takeaway
The model uses pre-operative abdominopelvic CT plus CA-125 and clinical factors, with predictive accuracy around 0.76.
When to use
Support the primary-debulking vs neoadjuvant-chemotherapy decision in advanced ovarian/tubal/peritoneal cancer.
How it works
Weighted sum: lesser sac +4; ASA 3–4 +3; perisplenic / small-bowel mesentery / SMA root each +2; age ≥ 60 / CA-125 ≥ 500 / suprarenal nodes / diffuse small bowel each +1. Bands 0 → ~ 5%, up to ≥ 9 → ~ 74% suboptimal.
Key points
- The model uses pre-operative abdominopelvic CT plus CA-125 and clinical factors, with predictive accuracy around 0.76.
- Higher scores (≥ 7, suboptimal rate ≥ 52%) favour neoadjuvant chemotherapy + interval debulking or referral to an experienced centre.
- It is decision-support, not a hard cut-off — combine with performance status, surgeon experience and multidisciplinary input.
- The CA-125 ≥ 500 U/mL threshold is specific to this model.
References
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Age ≥ 60 years (+1) | No |
|---|---|
| CA-125 ≥ 500 U/mL (+1) | No |
| Suprarenal retroperitoneal nodes (incl. supradiaphragmatic) > 1 cm (+1) | No |
| Diffuse small-bowel adhesions/thickening (+1) | No |
| Perisplenic lesion > 1 cm (+2) | No |
| Small-bowel mesentery lesion > 1 cm (+2) | No |
| Lesion at the root of the superior mesenteric artery > 1 cm (+2) | No |
| ASA class 3–4 (+3) | No |
| Lesser-sac lesion > 1 cm (+4) | No |
→Suidan score0 pts
- Total：0 pts (band 0) → suboptimal cytoreduction (residual > 1 cm) rate ~ 5%
- Scored items：No positive items (0 pts)
- Clinical note：Low suboptimal risk: favour primary debulking surgery (PDS) provided optimal cytoreduction is achievable
| Age ≥ 60 years (+1) | Yes |
|---|---|
| CA-125 ≥ 500 U/mL (+1) | Yes |
| Suprarenal retroperitoneal nodes (incl. supradiaphragmatic) > 1 cm (+1) | Yes |
| Diffuse small-bowel adhesions/thickening (+1) | Yes |
| Perisplenic lesion > 1 cm (+2) | Yes |
| Small-bowel mesentery lesion > 1 cm (+2) | Yes |
| Lesion at the root of the superior mesenteric artery > 1 cm (+2) | Yes |
| ASA class 3–4 (+3) | Yes |
| Lesser-sac lesion > 1 cm (+4) | Yes |
→Suidan score17 pts
- Total：17 pts (band ≥ 9) → suboptimal cytoreduction (residual > 1 cm) rate ~ 74%
- Scored items：Age ≥ 60 (+1), CA-125 ≥ 500 (+1), suprarenal nodes > 1 cm (+1), diffuse small-bowel adhesions/thickening (+1), perisplenic > 1 cm (+2), small-bowel mesentery > 1 cm (+2), SMA root > 1 cm (+2), ASA 3–4 (+3), lesser sac > 1 cm (+4)
- Clinical note：High suboptimal risk: favour neoadjuvant chemotherapy (NACT) + interval debulking surgery (IDS), or refer to an experienced gyn-onc centre / laparoscopic assessment (e.g. Fagotti score) before deciding
Verification & sources · governance
FAQ
Frequently asked questions
- What are the limits and cautions when using Ovarian Cancer Suidan Score (Suboptimal Cytoreduction Prediction)?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- Does Ovarian Cancer Suidan Score (Suboptimal Cytoreduction Prediction) upload patient data? Where is it calculated?
- Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.
- How is Ovarian Cancer Suidan Score (Suboptimal Cytoreduction Prediction) calculated in practice? Can you show a worked example?
- Inputs: Age ≥ 60 years (+1) No, CA-125 ≥ 500 U/mL (+1) No, Suprarenal retroperitoneal nodes (incl. supradiaphragmatic) > 1 cm (+1) No, Diffuse small-bowel adhesions/thickening (+1) No, Perisplenic lesion > 1 cm (+2) No, Small-bowel mesentery lesion > 1 cm (+2) No, Lesion at the root of the superior mesenteric artery > 1 cm (+2) No, ASA class 3–4 (+3) No… → Result: Suidan score 0 pts（Total: 0 pts (band 0) → suboptimal cytoreduction (residual > 1 cm) rate ~ 5%, Scored items: No positive items (0 pts), Clinical note: Low suboptimal risk: favour primary debulking surgery (PDS) provided optimal cytoreduction is achievable） Inputs: Age ≥ 60 years (+1) Yes, CA-125 ≥ 500 U/mL (+1) Yes, Suprarenal retroperitoneal nodes (incl. supradiaphragmatic) > 1 cm (+1) Yes, Diffuse small-bowel adhesions/thickening (+1) Yes, Perisplenic lesion > 1 cm (+2) Yes, Small-bowel mesentery lesion > 1 cm (+2) Yes, Lesion at the root of the superior mesenteric artery > 1 cm (+2) Yes, ASA class 3–4 (+3) Yes… → Result: Suidan score 17 pts（Total: 17 pts (band ≥ 9) → suboptimal cytoreduction (residual > 1 cm) rate ~ 74%, Scored items: Age ≥ 60 (+1), CA-125 ≥ 500 (+1), suprarenal nodes > 1 cm (+1), diffuse small-bowel adhesions/thickening (+1), perisplenic > 1 cm (+2), small-bowel mesentery > 1 cm (+2), SMA root > 1 cm (+2), ASA 3–4 (+3), lesser sac > 1 cm (+4), Clinical note: High suboptimal risk: favour neoadjuvant chemotherapy (NACT) + interval debulking surgery (IDS), or refer to an experienced gyn-onc centre / laparoscopic assessment (e.g. Fagotti score) before deciding）